Valiant Laboratories

Valiant Laboratories Net Tangible Assets

The Net Tangible Assets of Valiant Laboratories (VALIANTLAB.NS) as of Nov 4, 2026 is 3.11 B INR. In the previous year, Net Tangible Assets was 2.34 B INR — a change of 32.74% (higher).

Net Tangible Assets

3.11 BINR

YoY

32.74%

Last updated:

Net Tangible Assets of Valiant Laboratories is 2026 3.11 B INR. Net Tangible Assets of Valiant Laboratories was 2025 2.34 B INR. It decreases by 32.74% higher compared to the previous year.

The Valiant Laboratories Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2021
885.82 M INR
Jan 1, 2022
714.60 M INR
Jan 1, 2023
1.00 B INR
Jan 1, 2024
2.37 B INR
Jan 1, 2025
2.34 B INR
Jan 1, 2026
3.11 B INR
The Valiant Laboratories Net Tangible Assets history
YEARNet Tangible AssetsYoY
3.11 BINR+32.74%
2.34 BINR-1.12%
2.37 BINR+135.70%
1.00 BINR+40.63%
714.60 MINR-19.33%
885.82 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valiant Laboratories Stock analysis

What does Valiant Laboratories do? Valiant Laboratories Ltd manufactures paracetamol API/bulk drug for pharmaceutical applications, targeting medical conditions such as headache, muscle ache, arthritis, back ache, toothache, cold, and fever. The company operates a single manufacturing facility at Tarapur industrial estate, approximately 150 km from Nhava Sheva Port (JNPT), producing specialty chemicals and pharma intermediates for domestic and international markets. Its subsidiary, VALIANT ADVANCED SCIENCES PRIVATE LIMITED, supports the company's operations in the pharmaceutical sector. The firm's primary revenue comes from selling paracetamol API and specialty chemicals to pharmaceutical companies and distributors globally. Manufacturing focuses on high-demand applications like pain relief and fever treatment, with products distributed across India and abroad. The company leverages its Tarapur facility's proximity to Nhava Sheva Port for efficient export logistics. Valiant Laboratories Ltd serves the pharmaceutical industry by supplying essential active ingredients, particularly paracetamol, which is widely used in over-the-counter medications. The company's manufacturing capabilities for specialty chemicals and pharma intermediates cater to both domestic and international clients seeking reliable API sources. Its single-location production model ensures focused resource allocation for consistent output quality. Valiant Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valiant Laboratories stock

Net Tangible Assets of Valiant Laboratories is 3.11 B INR in 2026.

Net Tangible Assets of Valiant Laboratories changed from 2.34 B INR to 3.11 B INR, representing a 32.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Valiant Laboratories since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Valiant Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Valiant Laboratories

All Key Metrics — Valiant Laboratories